SKSteven Kao

Steven Kao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Steven Kao has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of rice bran arabinoxylan compound on quality of life of cancer patients during active treatment: a randomised placebo-controlled pilot trial

    by Soo Liang Ooi, Peter S. Micalos, Robert Zielinski, Judith Lacey, Suzanne Grant, Steven Kao, Terry Golombick, Sok Cheon Pak

    The effects of a plant-based immunomodulator, rice bran arabinoxylan compound (RBAC), on the quality of life (QoL) of cancer patients during active treatment are unclear. The RBAC-QoL study was a randomised, placebo-controlled, double-blind feasibility study to address the role of RBAC in cancer patients receiving systemic therapies. The primary outcome measure was patient-reported functional, symptom, and global QoL scores. Secondary and exploratory outcome measures included nutritional indices and cytokine changes. Adult patients (n = 29) with solid organ tumours (≥ stage II) undergoing systemic treatment were recruited from outpatient centres in New South Wales, Australia. Group allocation was assigned through stratified randomisation (RBAC = 12, placebo = 17). Interventions were either RBAC or matched placebo at 3 g/day for 24 weeks. The participants, oncologists, and data collectors were blinded. Data were collected from five study visits, 6 weeks apart. An intention-to-treat analysis was performed using repeated measure ANOVA with pairwise comparisons where statistical significance was observed. Data sets not conforming to normality were tested with nonparametric ANOVA-type statistics. The global QoL scores differed significantly between groups with a large effect size (p = 0.031, eta2[g] = 0.147). Pairwise comparisons found significant differences favouring the RBAC group at week 6 (p = 0.017, Cohen’s d = 1.119) and week 24 (p = 0.041, d = 0.970). Compared to the placebo group, the RBAC group showed significantly better role (p < 0.001) and social functioning (p = 0.037), while the cognitive functioning score difference was trending higher (p = 0.055). Regarding cancer symptoms, the placebo group reported significantly worse scores (p < 0.05) in fatigue, pain, dyspnoea, and appetite loss compared to the RBAC group. Significant elevations (p < 0.05) of cytokine interferon-γ, interleukin 1RA and 12p40, as well as total protein, were also detected in the RBAC group compared to placebo over time. These serum markers correlated positively with the global QoL scores, suggesting potential interactions of immune activity, nutritional status, and QoL. No intervention-related adverse events were reported in both groups. RBAC improves QoL beyond placebo during systemic cancer treatment, potentially through the immuno-nutritional pathway. Trial registration: Prospective registration on the Australian New Zealand Clinical Trials Registry (ANZCTR Reg No: ACTRN12619000562178p, 10/04/2019).


  • Top Cited Papers
    Open Access

    Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

    by N. Girard, J. Bar, P. Baas, C. Chouaid, D.C. Christoph, J.K. Field, R. Fietkau, M.C. Garassino, P. Garrido Lopez, V. Gregorc, et al.


  • Open Access

    Circulating tumor cell detection may offer earlier diagnosis in patients suspected of asbestos-related lung cancer

    by Helen Ke, Steven Kao, Nico van Zandwijk, John E.J. Rasko, Dannel Yeo


  • Open Access

    3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies

    by Huaikai Shi, Emma M. Rath, Ruby C. Y. Lin, Kadir Harun Sarun, Candice Julie Clarke, Brian C. McCaughan, Helen Ke, Anthony Linton, Kenneth Lee, Sonja Klebe, et al.

    Traditional studies using cancer cell lines are often performed on a two-dimensional (2D) cell culture model with a low success rate of translating to Phase I or Phase II clinical studies. In comparison, with the advent of developments three-dimensional (3D) cell culture has been championed as the latest cellular model system that better mimics in vivo conditions and pathological conditions such as cancer. In comparison to biospecimens taken from in vivo tissue, the details of gene expression of 3D culture models are largely undefined, especially in mesothelioma – an aggressive cancer with very limited effective treatment options. In this study, we examined the veracity of the 3D mesothelioma cell culture model to study cell-to-cell interaction, gene expression and drug response from 3D cell culture, and compared them to 2D cell and tumor samples. We confirmed via SEM analysis that 3D cells grown using the spheroid methods expressed highly interconnected cell-to-cell junctions. The 3D spheroids were revealed to be an improved mini-tumor model as indicated by the TEM visualization of cell junctions and microvilli, features not seen in the 2D models. Growing 3D cell models using decellularized lung scaffold provided a platform for cell growth and infiltration for all cell types including primary cell lines. The most time-effective method was growing cells in spheroids using low-adhesive U-bottom plates. However, not every cell type grew into a 3D model using the the other methods of hanging drop or poly-HEMA. Cells grown in 3D showed more resistance to chemotherapeutic drugs, exhibiting reduced apoptosis. 3D cells stained with H&E showed cell-to-cell interactions and internal architecture that better represent that of in vivo patient tumors when compared to 2D cells. IHC staining revealed increased protein expression in 3D spheroids compared to 2D culture. Lastly, cells grown in 3D showed very different microRNA expression when compared to that of 2D counterparts. In conclusion, 3D cell models, regardless of which method is used. Showed a more realistic tumor microenvironment for architecture, gene expression and drug response, when compared to 2D cell models, and thus are superior preclinical cancer models.


  • P16.02 Atezolizumab, Bevacizumab and Chemotherapy (IMpower150) in Stage IV Non-Small Cell Lung Cancer: The Australian Experience

    by S. Dean, H. Ainsworth, M. Alexander, D. Dharmaraj, R. O’cOnnell, P. Mitchell, J. Torres, A. Saqib, R. Ladwa, N. Pavlakis, et al.


  • Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.

    by Aurelien Marabelle, Philippe Alexandre Cassier, Marwan Fakih, Steven Chuan-Hao Kao, Dorte Nielsen, Antoine Italiano, Tormod Guren, Marloes Van Dongen, Kristen Renee Spencer, Giovanni M. Bariani, et al.

    4020 Background: Patients (pts) with anal squamous cell carcinoma (ASCC) have poor outcomes and few treatment options. We report a pooled analysis of pembrolizumab (pembro) antitumor activity and safety in the ASCC cohorts of the multicohort studies KEYNOTE-028 (NCT02054806; phase 1b) and KEYNOTE-158 (NCT02628067; phase 2), providing a robust sample size and longer follow-up. Methods: Eligible pts were aged ≥18 y with histologically/cytologically confirmed metastatic/unresectable ASCC, had prior failure of/intolerance to standard therapy or no standard therapy options, measurable disease (RECIST v1.1), ECOG PS 0/1, and a tissue sample evaluable for PD-L1/biomarkers (KEYNOTE-028 required PD-L1 positivity). Baseline PD-L1 expression was assessed using a prototype IHC assay (QualTek) in KEYNOTE-028 and the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies) in KEYNOTE-158. Pts received pembro 10 mg/kg Q2W (KEYNOTE-028) or 200 mg Q3W (KEYNOTE-158) for 2 y or until PD/unacceptable AEs. The primary endpoint in both studies was ORR (per RECIST v1.1). Secondary endpoints were duration of response (DOR), PFS, OS, and safety. Results: 137 pts with ASCC were treated in KEYNOTE-028 (n = 25) or KEYNOTE-158 (n = 112) and were included in this analysis (median age, 61 y; 83.2% women; 73.0% had PD-L1–positive tumors). Median follow-up was 11.7 mo; 124 pts (90.5%) had discontinued treatment. ORR (95% CI) was 10.9% (6.3%–17.4%). 8 pts had CR and 7 had PR. ORR (95% CI) by PD-L1 status was 14.0% (7.9%–22.4%) in the PD-L1 positive group and 3.3% (0.1%–17.2%) in the PD-L1 negative group. Among all treated pts, median DOR was not reached (range, 6.0+ to 57.5+ mo). By Kaplan-Meier estimation, 84.6% of responders had a DOR ≥24 mo. Median PFS was 2.1 mo (95% CI, 2.0–2.1) and median OS was 11.7 mo (95% CI, 8.8–14.5). The 12-mo PFS and OS rates were 14.5% and 47.4%. 85 pts (62.0%) had +1 treatment-related AE, 24 pts (17.5%) with grade 3–4 events (no grade 5 events). 32 pts (23.4%) had immune-mediated AEs; 2 pts (1.5%) had infusion related reactions. Conclusions: In pts with previously treated advanced ASCC, pembro showed durable antitumor activity, particularly in pts with PD-L1–positive tumors, and manageable toxicity. Clinical trial information: NCT02054806 (KEYNOTE-028), NCT02628067 (KEYNOTE-158) .


  • Open Access

    Patterns of care for stage III non–small cell lung cancer in Australia

    by Phillip Parente, Bryan A. Chan, Brett G. M. Hughes, Kevin Jasas, Rohit Joshi, Steven Kao, Fiona Hegi‐Johnson, Rina Hui, Sara McLaughlin‐Barrett, Ina Nordman, et al.

    Stage III non–small cell lung cancer (NSCLC) makes up a third of all NSCLC cases and is potentially curable. Despite this 5‐year survival rates remain between 15% and 20% with chemoradiation treatment alone given with curative intent. With the recent exciting breakthroughs in immunotherapy use (durvalumab) for stage III NSCLC, further improvements in patient survival can be expected.Most patients with stage III NSCLC present initially to their general practitioner (GP). The recommended time from GP referral to first specialist appointment is less than 14 days with treatment initiated within 42 days. Our review found that there is a shortfall in meeting these recommendations, however a number of initiatives have been established in Australia to improve timely and accurate diagnosis and treatment patterns. The lung cancer multidisciplinary team (MDT) is critical to consistency of evidence‐based diagnosis and treatment and can improve patient survival. We aimed to review current patterns of care and clinical practice recommendations for stage III NSCLC across Australia and identify opportunities to improve practice in referral, diagnosis and treatment pathways.


  • Open Access

    Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: Trends in Australia and a literature review

    by Anthony Linton, Steven Kao, Janette Vardy, Stephen Clarke, Nico van Zandwijk, Sonja Klebe

    The accurate diagnosis of malignant pleural mesothelioma (MPM) is essential for therapeutic and legal reasons. In 2006 the International Mesothelioma Panel advocated the use of a panel, including two mesothelial and two non-mesothelial immunohistochemical (IHC) markers. We assessed the changing use of IHC for the diagnosis of MPM in Australia over two decades in the context of current best practice. Patients with a confirmed clinico-pathological diagnosis of MPM who underwent extrapleural pneumonectomy or pleurectomy and/or decortication between 1988 and 2006 were identified from the cardiothoracic database at Royal Prince Alfred Hospital and combined with consecutive patients reviewed by the Dust Diseases Board between March 2007 and March 2009. Initial diagnostic pathology reports were reviewed. A total of 289 patients were identified. A median of six IHC stains per sample was performed (range 0-18): two (range 0-5) mesothelial markers, two (0-6) carcinoma markers and two epithelial markers. A trend to the higher usage of antibodies in epithelioid tumors versus biphasic and sarcomatoid tumors was noted (P = 0.148 and 0.389, respectively). Testing increased from a median of three stains per sample (1988-1997) to seven (2006-2009). Labeling specimens with > 2 mesothelial markers and > 2 carcinoma markers increased to 72 and 67 percent, respectively, after 2006. Reflecting the acceptance of diagnostic panels and increased availability of antibodies, an increase in the use of IHC stains for MPM diagnosis has occurred over the past two decades although uncertainty persists as to the optimal panel composition.